{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:13:40Z","timestamp":1773983620510,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12094-019-02055-5","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T12:38:34Z","timestamp":1550061514000},"page":"1312-1318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Expression of PDK1 in malignant pheochromocytoma as a new promising potential therapeutic target"],"prefix":"10.1007","volume":"21","author":[{"given":"X.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9076-5071","authenticated-orcid":false,"given":"Z.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"issue":"11","key":"2055_CR1","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","volume":"48","author":"G Eisenhofer","year":"2012","unstructured":"Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48(11):1739\u201349.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2055_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3803\/EnM.2017.32.2.152","volume":"32","author":"JWM Lenders","year":"2017","unstructured":"Lenders JWM, Eisenhofer G. Update on modern management of pheochromocytoma and paraganglioma. Endocrinol Metab (Seoul). 2017;32(2):152\u201361.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"9","key":"2055_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1055\/s-0029-1220687","volume":"41","author":"MR Druce","year":"2009","unstructured":"Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res. 2009;41(9):697\u2013702.","journal-title":"Horm Metab Res"},{"issue":"4","key":"2055_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","volume":"15","author":"C Jimenez","year":"2013","unstructured":"Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M, et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep. 2013;15(4):356\u201371.","journal-title":"Curr Oncol Rep"},{"key":"2055_CR5","doi-asserted-by":"publisher","first-page":"872713","DOI":"10.1155\/2012\/872713","volume":"2012","author":"G Parenti","year":"2012","unstructured":"Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giach\u00e8 V, Mannelli M. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma\/paraganglioma. J Oncol. 2012;2012:872713.","journal-title":"J Oncol"},{"key":"2055_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semcancer.2017.04.014","volume":"48","author":"PA Gagliardi","year":"2018","unstructured":"Gagliardi PA, Puliafito A, Primo L. PDK1: at the crossroad of cancer signaling pathways. Semin Cancer Biol. 2018;48:27\u201335.","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"2055_CR7","doi-asserted-by":"publisher","first-page":"E140","DOI":"10.3390\/cancers9100140","volume":"9","author":"A Emmanouilidi","year":"2017","unstructured":"Emmanouilidi A, Falasca M. Targeting PDK1 for chemosensitization of cancer cells. Cancers (Basel). 2017;9(10):E140.","journal-title":"Cancers (Basel)."},{"issue":"393","key":"2055_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2017.01.036","volume":"1","author":"Y Wang","year":"2017","unstructured":"Wang Y, Fu L, Cui M, Wang Y, Xu Y, Li M, et al. Amino acid transporter SLC38A3 promotes metastasis of non-small cell lung cancer cells by activating PDK1. Cancer Lett. 2017;1(393):8\u201315.","journal-title":"Cancer Lett"},{"issue":"11","key":"2055_CR9","first-page":"6329","volume":"35","author":"P Lohneis","year":"2015","unstructured":"Lohneis P, Darb-Esfahani S, Dietel M, Braicu I, Sehouli J, Arsenic R. PDK1 is expressed in ovarian serous carcinoma and correlates with improved survival in high-grade tumors. Anticancer Res. 2015;35(11):6329\u201334.","journal-title":"Anticancer Res"},{"issue":"5","key":"2055_CR10","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3324\/haematol.2013.096487","volume":"99","author":"J Zabkiewicz","year":"2014","unstructured":"Zabkiewicz J, Pearn L, Hills RK, Morgan RG, Tonks A, Burnett AK, et al. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica. 2014;99(5):858\u201364.","journal-title":"Haematologica"},{"issue":"25","key":"2055_CR11","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1038\/onc.2015.393","volume":"35","author":"J Du","year":"2016","unstructured":"Du J, Yang M, Chen S, Li D, Chang Z, Dong Z. PDK1 promotes tumor growth and metastasis in a spontaneous breast cancer model. Oncogene. 2016;35(25):3314\u201323.","journal-title":"Oncogene"},{"issue":"7","key":"2055_CR12","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1007\/s13277-015-3187-7","volume":"36","author":"X Zhang","year":"2015","unstructured":"Zhang X, Wang X, Xu T, Zhong S, Shen Z. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma. Tumour Biol. 2015;36(7):5273\u201381.","journal-title":"Tumour Biol"},{"key":"2055_CR13","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3390\/md8041469","volume":"8","author":"JY Zhang","year":"2010","unstructured":"Zhang JY, Tao LY, Liang YJ, Chen LM, Mi YJ, Zheng LS, et al. Anthracenedione derivatives as anticancer agents isolated from secondary metabolites of the mangrove endophytic fungi. Mar Drugs. 2010;8:1469\u201381.","journal-title":"Mar Drugs"},{"issue":"1","key":"2055_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12931-018-0910-0","volume":"19","author":"TL Suber","year":"2018","unstructured":"Suber TL, Nikolli I, O\u2019Brien ME, Londino J, Zhao J, Chen K, et al. FBXO17 promotes cell proliferation through activation of Akt in lung adenocarcinoma cells. Respir Res. 2018;19(1):206.","journal-title":"Respir Res"},{"issue":"1","key":"2055_CR15","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1186\/s12885-018-4811-x","volume":"18","author":"F Jouali","year":"2018","unstructured":"Jouali F, Marchoudi N, Talbi S, Bilal B, El Khasmi M, Rhaissi H, et al. Detection of PIK3\/AKT pathway in Moroccan population with triple negative breast cancer. BMC Cancer. 2018;18(1):900.","journal-title":"BMC Cancer"},{"issue":"6","key":"2055_CR16","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1245\/s10434-016-5097-3","volume":"23","author":"Y Hisamatsu","year":"2016","unstructured":"Hisamatsu Y, Oki E, Otsu H, Ando K, Saeki H, Tokunaga E, et al. Effect of EGFR and p-AKT overexpression on chromosomal instability in gastric cancer. Ann Surg Oncol. 2016;23(6):1986\u201392.","journal-title":"Ann Surg Oncol"},{"issue":"28","key":"2055_CR17","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1038\/s41388-018-0236-x","volume":"37","author":"N Coant","year":"2018","unstructured":"Coant N, Garc\u00eda-Barros M, Zhang Q, Obeid LM, Hannun YA. AKT as a key target for growth promoting functions of neutral ceramidase in colon cancer cells. Oncogene. 2018;37(28):3852\u201363.","journal-title":"Oncogene"},{"issue":"3","key":"2055_CR18","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.18632\/oncotarget.14021","volume":"8","author":"K Brasseur","year":"2017","unstructured":"Brasseur K, G\u00e9vry N, Asselin E. Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget. 2017;8(3):4008\u201342.","journal-title":"Oncotarget"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-019-02055-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02055-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02055-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T19:28:30Z","timestamp":1581535710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-019-02055-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["2055"],"URL":"https:\/\/doi.org\/10.1007\/s12094-019-02055-5","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,13]]},"assertion":[{"value":"2 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was in accordance with the ethical standards and was approved by The First Affiliated Hospital of Wenzhou Medical University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The datasets generated and\/or analysed during this study are available from the first author and corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}